Patents by Inventor Robert A. Volkmann

Robert A. Volkmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptide conjugates of microtubule-targeting agents as therapeutics
    Patent number: 12234212
    Abstract: The present invention relates to peptide conjugates of microtubule-targeting agents such as maytansinoid derivatives which are useful for the treatment of diseases such as cancer.
    Type: Grant
    Filed: January 11, 2023
    Date of Patent: February 25, 2025
    Assignee: Cybrexa 3, Inc.
    Inventors: Daniel Richard Marshall, Johanna Marie Csengery, Robert John Maguire, Robert A. Volkmann
  • HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20250034145
    Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
    Type: Application
    Filed: February 29, 2024
    Publication date: January 30, 2025
    Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser
  • Heteroaromatic NMDA receptor modulators and uses thereof
    Patent number: 12162890
    Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated modulate the NMDA receptor.
    Type: Grant
    Filed: December 14, 2021
    Date of Patent: December 10, 2024
    Assignee: Novartis AG
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger
  • Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B
    Patent number: 12161624
    Abstract: Compounds that selectively negatively modulate NMDA receptors containing an NR1/NR2B subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.
    Type: Grant
    Filed: August 10, 2021
    Date of Patent: December 10, 2024
    Assignee: Novartis AG
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti
  • N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[C]pyrrole negative allosteric modulators of NR2B
    Patent number: 12145909
    Abstract: The present disclosure relates to N-alkylaryl-5-oxyaryl-octadihydrocyclopent[c]pyrrole negative allosteric modulators of NR2B receptors useful in the treatment of neurological diseases having the Formula I: where R1, R2, L1, L2, X, Y, and Y? are described therein.
    Type: Grant
    Filed: May 3, 2022
    Date of Patent: November 19, 2024
    Assignee: Novartis AG
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti
  • NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20240294546
    Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.
    Type: Application
    Filed: September 14, 2023
    Publication date: September 5, 2024
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger, Yuelian Xu
  • HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20240199617
    Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo [2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
    Type: Application
    Filed: July 13, 2023
    Publication date: June 20, 2024
    Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser
  • PEPTIDE CONJUGATES OF MICROTUBULE-TARGETING AGENTS AS THERAPEUTICS
    Publication number: 20240067616
    Abstract: The present invention relates to peptide conjugates of microtubule-targeting agents such as maytansinoid derivatives which are useful for the treatment of diseases such as cancer.
    Type: Application
    Filed: January 11, 2023
    Publication date: February 29, 2024
    Inventors: Daniel Richard Marshall, Johanna Marie Csengery, Robert John Maguire, Robert A. Volkmann
  • PEPTIDE CONJUGATES OF CYTOTOXINS AS THERAPEUTICS
    Publication number: 20240010755
    Abstract: The present invention relates to peptide conjugates of cytotoxins such as topoisomerase I inhibitors which are useful for the treatment of diseases such as cancer.
    Type: Application
    Filed: February 27, 2023
    Publication date: January 11, 2024
    Inventors: Daniel Richard Marshall, Johanna Marie Csengery, Robert John Maguire, Robert A. Volkmann
  • Oxabicycloheptane prodrugs
    Patent number: 11866444
    Abstract: The present invention provides a compound having the structure:
    Type: Grant
    Filed: January 27, 2022
    Date of Patent: January 9, 2024
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Robert A. Volkmann, Anthony Marfat
  • HETEROARYL AMIDE INHIBITORS OF CD38
    Publication number: 20230382901
    Abstract: Disclosed are heteroaryl amide inhibitors of CD38 and methods of making and using the same in disease and disorder treatment.
    Type: Application
    Filed: October 8, 2021
    Publication date: November 30, 2023
    Inventors: Robert A. VOLKMANN, Jotham W. COE, Eric VERDIN, Rosalba PERRONE, Margaret JACKSON, Frederick R. NELSON, Elena SILVA, Steve FELSTEAD
  • NMDA receptor modulators and uses thereof
    Patent number: 11807650
    Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.
    Type: Grant
    Filed: January 27, 2022
    Date of Patent: November 7, 2023
    Assignee: Novartis AG
    Inventors: David R. Anderson, Robert Volkmann, Frank Menniti, Christopher Fanger, Yuelian Xu
  • Thienopyrimidinone NMDA receptor modulators and uses thereof
    Patent number: 11648253
    Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.
    Type: Grant
    Filed: August 27, 2021
    Date of Patent: May 16, 2023
    Assignee: Novartis AG
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger
  • Peptide conjugates of cytotoxins as therapeutics
    Patent number: 11634508
    Abstract: The present invention relates to peptide conjugates of cytotoxins such as topoisomerase I inhibitors which are useful for the treatment of diseases such as cancer.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: April 25, 2023
    Assignee: Cybrexa 2, Inc.
    Inventors: Daniel Richard Marshall, Johanna Marie Csengery, Robert John Maguire, Robert A. Volkmann
  • HETEROAROMATIC NMDA RECEPTOR MODULATORS AND USES THEREOF
    Publication number: 20230023543
    Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated modulate the NMDA receptor.
    Type: Application
    Filed: December 14, 2021
    Publication date: January 26, 2023
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger
  • Peptide conjugates of microtubule-targeting agents as therapeutics
    Patent number: 11555019
    Abstract: The present invention relates to peptide conjugates of microtubule-targeting agents such as maytansinoid derivatives which are useful for the treatment of diseases such as cancer.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: January 17, 2023
    Assignee: Cybrexa 3, Inc.
    Inventors: Daniel Richard Marshall, Johanna Marie Csengery, Robert John Maguire, Robert A. Volkmann
  • SELECTIVE OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE MODULATORS OF NR2B
    Publication number: 20230012073
    Abstract: Compounds that selectively negatively modulate NMDA receptors containing an NR1/NR2B subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.
    Type: Application
    Filed: August 10, 2021
    Publication date: January 12, 2023
    Applicant: Cadent Therapeutics, Inc.
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti
  • Thienopyrimidinone NMDA receptor modulators and uses thereof
    Patent number: 11541057
    Abstract: Disclosed herein, in part, are methods of treating neurological disorders, e.g., schizophrenia and major depressive disorder, comprising administering an effective amount of a disclosed heterocyclic compound. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: January 3, 2023
    Assignee: Cadent Therapeutics, Inc.
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger
  • Heteroaromatic NMDA receptor modulators and uses thereof
    Patent number: 11542264
    Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: January 3, 2023
    Assignee: Cadent Therapeutics, Inc.
    Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser
  • N-ALKYLARYL-5-OXYARYL-OCTAHYDRO-CYCLOPENTA[C]PYRROLE NEGATIVE ALLOSTERIC MODULATORS OF NR2B
    Publication number: 20220274925
    Abstract: The present disclosure relates to N-alkylaryl-5-oxyaryl-octadihydrocyclopent[c]pyrrole negative allosteric modulators of NR2B receptors useful in the treatment of neurological diseases having the Formula I: where R1, R2, L1, L2, X, Y, and Y? are described therein.
    Type: Application
    Filed: May 3, 2022
    Publication date: September 1, 2022
    Applicant: CADENT THERAPEUTICS, INC.
    Inventors: David R. ANDERSON, Robert A. VOLKMANN, Frank S. MENNITI